Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | FPR3 | P25089 | 1/20 | 0.36 |
| ▸ | FPR2 | P25090 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.34 |
| ▸ | FDPS | P14324 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22212153 | 0.77 | — | — | |
| SCHEMBL23609328 | 0.75 | EGLN3 (0.44) | EGLN3LOXL2NAMPTCYP1A2CYP3A4 | |
| SCHEMBL18072248 | 0.75 | EGLN3 (0.53) | EGLN3LOXL2NAMPTCYP1A2CYP3A4 | |
| SCHEMBL20445070 | 0.75 | EGLN3 (0.53) | EGLN3LOXL2NAMPTCYP1A2CYP3A4 | |
| SCHEMBL23875821 | 0.73 | EGLN3 (0.37) | EGLN3LOXL2NAMPTCYP1A2CYP3A4 | |
| SCHEMBL3633388 | 0.73 | EGLN3 (0.38) | EGLN3LOXL2NAMPTCYP1A2CYP3A4 | |
| SCHEMBL23875663 | 0.72 | — | — | |
| SCHEMBL23875762 | 0.71 | EGLN3 (0.36) | EGLN3LOXL2NAMPTCYP1A2CYP3A4 | |
| SCHEMBL19755640 | 0.71 | EGLN3 (0.49) | EGLN3LOXL2NAMPTCYP1A2CYP3A4 | |
| Thiourea SCHEMBL8177690 | 0.71 | EGLN3 (0.42) | EGLN3MAPTCYP19A1FDPSSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9150561-B2 | Thiazole derivatives and use thereof | MERCK SERONO S.A. (CH) | 2015-10-06 | — | — | US | disclosed |
| US-20140228365-A1 | THIAZOLE DERIVATIVES AND USE THEREOF | MERCK SERONO S.A. (CH) | 2014-08-14 | — | — | US | disclosed |
| US-8802861-B2 | Thiazole derivatives and use thereof | MERCK SERONO SA (CH) | 2014-08-12 | — | — | US | disclosed |
| US-20090029998-A1 | Thiazole Derivatives and Use Thereof | APPLIED RESEARCH SYSTEM ARS HOLDING N.V. (NL) | 2009-01-29 | — | — | US | disclosed |
| EP-1709019-B1 | THIAZOLE DERIVATIVES AND USE THEREOF | APPLIED RESEARCH SYSTEMS (AN) | 2007-08-08 | — | — | EP | disclosed |
| EP-1709019-A2 | THIAZOLE DERIVATIVES AND USE THEREOF | Applied Research Systems ARS Holding N.V. (AN) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005068444-A2 | THIAZOLE DERIVATIVES AND USE THEREOF | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2005-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228365-A1 | THIAZOLE DERIVATIVES AND USE THEREOF | PF4, TEC, PDGFRB | EGLN3 4374/4885LOXL2 2804/4885NAMPT 2049/4885 |
| US-20090029998-A1 | Thiazole Derivatives and Use Thereof | PDGFRB, PDGFRA, TEC | EGLN3 4514/4885LOXL2 1981/4885NAMPT 3494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.